Hence, it would be of great interest to compare small-sized ABD-fused NDCs with trastuzumab or trastuzumab-based ADCs also in the context of HER2-expressing brain metastases treatment, which are frequently linked with poor prognosis for breast cancer patients. Here, ERBB2 is linked to breast carcinoma.